Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

March 31, 2010

Conditions
Relapsed Breast CancerNeoplasms, Breast
Interventions
DRUG

Lapatinib

Small molecule tyrosine kinase inhibitor

DRUG

Capecitabine

Chemotherapy

DRUG

Docetaxel

Chemotherapy

DRUG

nab-Paclitaxel

Chemotherapy

Trial Locations (28)

10016

GSK Investigational Site, New York

20007

GSK Investigational Site, Washington D.C.

21237

GSK Investigational Site, Baltimore

22031

GSK Investigational Site, Fairfax

24211

GSK Investigational Site, Abingdon

29150

GSK Investigational Site, Sumter

30045

GSK Investigational Site, Lawrenceville

30341

GSK Investigational Site, Atlanta

32806

GSK Investigational Site, Orlando

33021

GSK Investigational Site, Hollywood

33328

GSK Investigational Site, Fort Lauderdale

38801

GSK Investigational Site, Tupelo

46227

GSK Investigational Site, Indianapolis

55426

GSK Investigational Site, Minneapolis

60099

GSK Investigational Site, Zion

70006

GSK Investigational Site, Metairie

70112

GSK Investigational Site, New Orleans

71913

GSK Investigational Site, Hot Springs

78229

GSK Investigational Site, San Antonio

78705

GSK Investigational Site, Austin

84403

GSK Investigational Site, Ogden

90806

GSK Investigational Site, Long Beach

91505

GSK Investigational Site, Burbank

92346

GSK Investigational Site, Highland

92801

GSK Investigational Site, Anaheim

95819

GSK Investigational Site, Sacramento

08043

GSK Investigational Site, Voorhees Township

87131-0001

GSK Investigational Site, Albuquerque

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00479856 - Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer | Biotech Hunter | Biotech Hunter